Compare Devine Impex with Similar Stocks
Dashboard
Weak Long Term Fundamental Strength with a -2.23% CAGR growth in Net Sales over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 0.06
- The company has been able to generate a Return on Equity (avg) of 0.23% signifying low profitability per unit of shareholders funds
Flat results in Sep 25
With ROE of 0.3, it has a Very Expensive valuation with a 0.7 Price to Book Value
Below par performance in long term as well as near term
Stock DNA
Trading & Distributors
INR 9 Cr (Micro Cap)
237.00
60
0.00%
0.00
0.29%
0.66
Total Returns (Price + Dividend) 
Devine Impex for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News
When is the next results date for Devine Impex Ltd?
The next results date for Devine Impex Ltd is scheduled for 12 February 2026....
Read full news article
Devine Impex Ltd is Rated Strong Sell
Devine Impex Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 16 December 2025, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 28 December 2025, providing investors with the latest view of the company’s position in the market.
Read full news article
Devine Impex Faces Mixed Market Assessment Amidst Flat Financials and Sideways Technicals
Devine Impex, a player in the Trading & Distributors sector, has experienced a shift in market evaluation reflecting a complex interplay of financial performance, valuation metrics, and technical indicators. The company’s recent financial results and market behaviour have prompted a revision in its analytical perspective, highlighting challenges in growth and market positioning.
Read full news article Announcements 
Board Meeting Intimation for Considering And Approving Unaudited Financial Results For The Quarter Ended 31.12.2025
04-Feb-2026 | Source : BSEDevine Impex Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2026 inter alia to consider and approve Unaudited Financial Results for the quarter ended 31.12.2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
13-Jan-2026 | Source : BSECompliance Certificate under Regulation 74(5) of DP Regulations
Closure of Trading Window
31-Dec-2025 | Source : BSESubmission of intimation of closure of trading window
Corporate Actions 
12 Feb 2026
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Non Institution
None
Held by 1 Schemes (0.02%)
Held by 0 FIIs
Manju Jain (13.11%)
Synergy Cosmetics (exim) Limited (7.76%)
17.92%
Quarterly Results Snapshot (Standalone) - Sep'25 - QoQ
QoQ Growth in quarter ended Sep 2025 is 208.33% vs -87.10% in Jun 2025
QoQ Growth in quarter ended Sep 2025 is 400.00% vs 0.00% in Jun 2025
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is -31.51% vs 52.08% in Sep 2024
Growth in half year ended Sep 2025 is 0.00% vs 166.67% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'24
YoY Growth in nine months ended Dec 2024 is 48.61% vs -15.29% in Dec 2023
YoY Growth in nine months ended Dec 2024 is 100.00% vs 100.00% in Dec 2023
Annual Results Snapshot (Standalone) - Mar'25
YoY Growth in year ended Mar 2025 is 13.64% vs -1.12% in Mar 2024
YoY Growth in year ended Mar 2025 is -25.00% vs -20.00% in Mar 2024






